826-01-7

Basic information

• Product Name: (αS)-α-(Aminomethyl)-4-hydroxybenzenemethanol
• Synonyms: (1S)-2-Amino-1-(4-hydroxyphenyl)ethanol;(S)-2-Amino-1-(4-hydroxyphenyl)ethanol;(αS)-α-(Aminomethyl)-4-hydroxybenzenemethanol;[S,(+)]-α-(Aminomethyl)-4-hydroxybenzyl alcohol
• CAS NO: 826-01-7
• Molecular Formula: C₈H₁₁NO₂
• Molecular Weight: 153.17844
• Mol File: 826-01-7.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (αS)-α-(Aminomethyl)-4-hydroxybenzenemethanol(CAS DataBase Reference)
• NIST Chemistry Reference: (αS)-α-(Aminomethyl)-4-hydroxybenzenemethanol(826-01-7)
• EPA Substance Registry System: (αS)-α-(Aminomethyl)-4-hydroxybenzenemethanol(826-01-7)

Safety Data

• Hazardous Substances Data: 826-01-7(Hazardous Substances Data)

Usage

Description

(αS)-α-(Aminomethyl)-4-hydroxybenzenemethanol, commonly known as carbidopa, is a pharmaceutical compound utilized in the treatment of Parkinson's disease. It functions by inhibiting the peripheral decarboxylation of levodopa, a precursor to dopamine, thereby increasing the amount of levodopa that can reach the brain. In the brain, levodopa is converted into dopamine, which helps to alleviate the symptoms associated with Parkinson's disease.

Uses

Used in Pharmaceutical Industry:
Carbidopa is used as an active pharmaceutical ingredient for the treatment of Parkinson's disease. It is particularly effective in increasing the bioavailability of levodopa, allowing for more of the compound to reach the brain and be converted into dopamine. This conversion helps to alleviate the motor symptoms of Parkinson's disease, such as tremors, rigidity, and bradykinesia.
Additionally, carbidopa is used as a co-formulated agent with levodopa to enhance the overall effectiveness of the treatment and reduce side effects like nausea and vomiting. This combination therapy is typically taken orally and has been found to be well-tolerated and effective when prescribed by a healthcare professional.

Upstream product

• 104-14-3 octopamine 
• 2628-17-3 4-Vinylphenol 
• 831171-94-9 butyric acid 2-(9H-fluoren-9-ylmethoxycarbonylamino)-1-(4-hydroxy-phenyl)-ethyl ester 
• 831171-92-7 [2-hydroxy-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid 9H-fluoren-9-ylmethyl ester 
• 123-08-0 4-hydroxy-benzaldehyde 
• 56-40-6 glycine 
• 831172-01-1 [2-hydroxy-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid 9H-fluoren-9-ylmethyl ester 
• 1268725-97-8 (S)-1-(4-hydroxyphenyl)-2-nitroethanol 
• 200405-33-0 (S)-(+)-acetic acid 4-(2-benzyloxycarbonylamino-1-hydroxy-ethyl)phenyl ester 

Relevant articles and documents

Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia

Ulotaront (SEP-363856) is a trace-amine associated receptor 1 (TAAR1) agonist with 5-HT1A receptor agonist activity in Phase 3 clinical development, with FDA Breakthrough Therapy Designation, for the treatment of schizophrenia. TAAR1 is a G-protein-coupled receptor (GPCR) that is expressed in cortical, limbic, and midbrain monoaminergic regions. It is activated by endogenous trace amines, and is believed to play an important role in modulating dopaminergic, serotonergic, and glutamatergic circuitry. TAAR1 agonism data are reported herein for ulotaront and its analogues in comparison to endogenous TAAR1 agonists. In addition, a human TAAR1 homology model was built around ulotaront to identify key interactions and attempt to better understand the scaffold-specific TAAR1 agonism structure-activity relationships.

Highly enantioselective henry reactions in water catalyzed by a copper tertiary amine complex and applied in the synthesis of (S)-N-trans-feruloyl octopamine

It's in the water! A new copper tertiary amine complex was prepared and applied in asymmetric Henry reactions in water and in the short synthesis of (S)-N-trans-feruloyl octopamine. This catalytic system provided an approach to the enantioselective Henry reaction of aldehydes with hydroxyl substituents (see graphic).

COMPOUNDS AND METHODS FOR TREATMENT OF CANCER AND MODULATION OF PROGRAMMED CELL DEATH FOR MELANOMA AND OTHER CANCER CELLS

Compounds and related methods for synthesis, and the use of compounds and combination therapies for the treatment of cancer and modulation of apoptosis in cells are disclosed. The generation of synthetic combinatorial libraries and the evaluation of library member compounds regarding induction of apoptosis selectively in cancer cells are disclosed. Compounds, methods of making the compounds, and therapeutic methods with application against breast cancer cells, melanoma cancer cells, colon cancer cells, and other cancer cells are described.